title: [TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING TRANSVESICAL PROSTATECTOMY].
abstract: This study examines the efficacy and safety of phosphodiesterase type 5 (PDE-5) inhibitors in treating erectile dysfunction after transvesical prostatectomy. The study involved 63 men aged 55 to 68 years, divided into two groups--29 and 34 patients, respectively. Patients in group 1 received 50 mg of sildenafil citrate (Ereksezil®) on a daily basis, in group 2--100 mg of sildenafil citrate (Ereksezil®) on demand. Postoperative visits were scheduled at the stage of screening, then after a month of treatment and on day 14 after treatment completion (3 visits altogether). Changes of patients' complaints according to IIEF-15 questionnaire showed a significant improvement in erectile function and its components of sexual life satisfaction in both groups of patients, but more significantly with regular medication intake, which has a positive impact on patients' quality of life. At the same time, treatment by PDE-5 inhibitors did not affect the maximum urinary flow rate and residual urine volume. Given the high incidence of the postoperative erectile dysfunction, postoperative administration of PDE-5 inhibitors is relevant and promising.
authors.forename: P I
authors.initials: PI
authors.lastname: Motin
authors.forename: M I
authors.initials: MI
authors.lastname: Andrjuhin
authors.forename: S A
authors.initials: SA
authors.lastname: Pul'bere
authors.forename: O Ju
authors.initials: OJ
authors.lastname: Alekseev
authors.forename: N K
authors.initials: NK
authors.lastname: Agaev
mesh_terms: D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy / Q000503:physiopathology; D011470:Prostatic Hyperplasia / Q000503:physiopathology / Q000601:surgery*; D000068677:Sildenafil Citrate / Q000008:administration & dosage*; D020728:Transurethral Resection of Prostate / Q000009:adverse effects*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D000068677:Sildenafil Citrate